Leo Pharma executive on EU progress: This is a huge milestone for us
Now that the CHMP has recommended approval for the eczema drug Adtralza, Leo Pharma can start preparing for the firm's most significant launch in years.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
On Friday, Leo Pharma received an approval recommendation for the drug tralokinumab, which will be known as Adtralza onwards, for treating eczema. This is the culmination of five years' hard work, and for the the Danish dermatology company, it is the first time it has full control of a global launch relating to one of its biological drugs.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma's board now has one person less
For subscribers
.jpg&w=384&q=75)
